ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00019568272026-05-13 · Issuer identity, ticker, exchange, fiscal year end, and filing inventory.SEC XBRL companyfactsSEC companyfacts for CIK 00019568272026-05-13 · XBRL cross-checks for financial statement facts.Annual reportAbivax FY2025 Form 20-F2026-03-23 · Business overview, risk factors, FY2025 financials, liquidity, IP, controls, and competition.Company 6-K exhibitAbivax FY2025 results release2026-03-23 · Cash runway, FY2025 financial summary, DSMB update, and 2026 catalysts.Company 6-K exhibitABTECT Phase 3 induction results2025-07-22 · Positive induction results and trial population details.Company 6-K exhibitRoyalty-certificate repurchase and ADS issuance2026-05-05 · Royalty overhang reduction, cash use, dilution, and runway update.Peer annual reportAbbVie 2025 Form 10-K2026-02-20 · Official competitive context for Skyrizi, Rinvoq, Humira, biologics, and oral IBD competition.Peer annual reportTakeda fiscal 2024 Form 20-F2025-06-25 · Official competitive context for Entyvio and IBD franchise scale.